End-of-day quote
Other stock markets
|
5-day change | 1st Jan Change | ||
13,400 KRW | -0.59% | -2.05% | -41.36% |
Summary
- From a short-term investment perspective, the company presents a deteriorated fundamental situation
Strengths
- The prospective high growth for the next fiscal years is among the main assets of the company
- The earnings growth currently anticipated by analysts for the coming years is particularly strong.
- Given the positive cash flows generated by its business, the company's valuation level is an asset.
- Analysts covering this company mostly recommend stock overweighting or purchase.
- The average target price set by analysts covering the stock is above current prices and offers a tremendous appreciation potential.
- Over the past twelve months, analysts' opinions have been strongly revised upwards.
- The divergence of price targets given by the various analysts who make up the consensus is relatively low, suggesting a consensus method of evaluating the company and its prospects.
Weaknesses
- For the last twelve months, the trend in sales revisions has been clearly going down, which emphasizes downgraded expectations from the analysts.
- The sales outlook for the group was lowered in the last twelve months. This change in forecast points out a decline in activity as well as pessimistic analyses of the company.
- For the past year, analysts have significantly revised downwards their profit estimates.
- For the last twelve months, the analysts covering the company have given a bearish overview of EPS estimates, resulting in frequent downward revisions.
- Over the past four months, analysts' average price target has been revised downwards significantly.
- Prospects from analysts covering the stock are not consistent. Such dispersed sales estimates confirm the poor visibility into the group's activity.
- The company's earnings releases usually do not meet expectations.
Ratings chart - Surperformance
Sector: Advanced Medical Equipment & Technology
1st Jan change | Capi. | Investor Rating | ESG Refinitiv | |
---|---|---|---|---|
-41.36% | 148M | - | ||
-3.25% | 15.01B | - | ||
-38.91% | 2.8B | C- | ||
-12.68% | 2.45B | - | ||
-12.18% | 1.46B | - | - | |
-.--% | 1.12B | - | - | |
+41.68% | 518M | - | ||
+92.56% | 505M | B+ | ||
+14.23% | 245M | C | ||
+2.04% | 183M | - |
Financials
Valuation
Momentum
Consensus
Business Predictability
- Stock Market
- Equities
- A228670 Stock
- Ratings Ray Co., Ltd.